Fahrer Group - Immunology

Photo: Left to Right:Associate Professor Aude Fahrer, Dr. Christina Carroll and Dr. Erin Andrew Photo: Left to Right: Dr. Lawrence Wilson, Associate Professor Aude Fahrer, Dr. Angelo Theodoratos, Dr. Katharine Gosling, Dr. Christina Carroll and Mr. Joshua Miasek Photo: Left to Right: Mr.Andrew Almonte, Associate Professor Aude Fahrer, Mr. George Cavic Photo: Left to Right: Mr. George Cavic, Mr. Andrew Almonte, Associate Professor Aude Fahrer and Ms. Ruth Purcell

The Group is focused on two main areas of research at the moment:

  1. A very simple and inexpensive cancer immunotherapy treatment I have come up with, involving a single injection of an immune stimulant into a tumour.
  2. A bioinformatics study looking for novel proteins in different genomes. We have just recently around 2000 novel proteins from humans and mice.

Group Leader

Honorary Lecturer

Divisional Visitor

Honours Students

PhB Student

PhD Student


Filter by keyword

Selected publications

  • Almonte, A, Cavic, G, Neeman, T, Enders, A, Fahrer, A.M. (2022) Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience, Journal for ImmunoTherapy of Cancer, Volume 10, Issue 11.
  • Carroll, C, Andrew, E, Malik, L et al. (2021), Simple and effective bacterial-based intratumoral cancer immunotherapy, Journal for ImmunoTherapy of Cancer, vol. 9, no. 9.
  • Almonte, A, Rangarajan, H, Yip, D et al. (2020) How does the gut microbiome influence immune checkpoint blockade therapy?, Immunology and Cell Biology, 99: 361–372.
  • Wang, J, Gross, G, Andrew, E et al. (2019) A predicted novel protein isoform of HOXA9, Leukemia Research, 82:7-10.
  • Carroll, C, Altin, J, Neeman, T et al. (2015) Repeated fine-needle aspiration of solid tumours in mice allows the identification of multiple infiltrating immune cell types, Journal of Immunological Methods, 425:102-107.
  • Wilson L.O., Spriggs A, Taylor J.M., Fahrer A.M. (2014) A novel splicing outcome reveals more than 2000 new mammalian protein isoforms.Bioinformatics. Jan 15;30(2):151-6
  • Wilson, L.O; Fahrer, A.M. (2013) Condensins, chromatin remodeling and gene transcription, Chromatin Remodelling, Dr Danuta Radzioch (Ed.), ISBN: 978-953-51-1087-3 InTech. Also available from InTech Open
  • Fahrer, Aude M, (2012). A proposal for a simple and inexpensive therapeutic cancer vaccine, Immunology and Cell Biology 90 (3) 310-313
  • Theodoratos, Angelo; Wilson, Laurence O. W.; Gosling, Katharine M.; et al. (2012) Splice variants of the condensin II gene Ncaph2 include alternative reading frame translations of exon 1, Febs Journal 279 (8) 1422-1432
  • Theodoratos, A; Whittle, B; Enders, A; et al. (2010), Mouse strains with point mutations in TAP1 and TAP2, Immunology and Cell Biology 88 (1) 72-78
  • Gosling, KM; Goodnow, CC; Verma, NK; et al (2008), Defective T-cell function leading to reduced antibody production in a kleisin-beta mutant mouse, Immunology 125 (2) 208-217
  • Gosling, KM; Makaroff, LE; Theodoratos, A; et al (2007) A mutation in a chromosome condensin II subunit, kleisin beta, specifically disrupts T cell development, Proceedings of the National Academy Of Sciences of the United States Of America 104 (30) 12445-12450
  • Liston, A; Lesage, S; Gray, DHD; et al, (2004) Generalized resistance to thymic deletion in the NOD mouse: A polygenic trait characterized by defective induction of Bim, Immunity 21 (6) 817-830
  • Fahrer, AM; Bazan, JF; Papathanasiou, P; et al (2001) A genomic view of immunology, Nature 409 (6822) 836-838
  • Fahrer, AM; Konigshofer, Y; Kerr, EM; et al,(2001) Attributes of gamma delta intraepithelial lymphocytes as suggested by their transcriptional profile, Proceedings of the National Academy Of Sciences of the United States Of America 98 (18) 10261-10266.

All publications

Bacteria blasting cancer treatment shows promise

Story | Tuesday 28 September 2021
A low-cost, non-toxic cancer treatment has been developed by researchers at The Australian National University (ANU). The treatment uses dead bacteria to help kick-start the immune system and shrink cancer.

Aude Fahrer, putting cancer on trial

Story | Tuesday 18 December 2018
Aude Fahrer's work aims to activate the immune cells responsible for attacking cancer, in a simple, low cost way.

Putting cancer on trial

Story | Friday 20 October 2017

Erin Andrew wins ANU 3 Minute Thesis competition

Story | Thursday 7 September 2017
Erin Andrew from the Research School of Biology (RSB) has won the 2017 ANU 3MT (3 Minute Thesis) competition

Aude Fahrer

Story | Tuesday 21 January 2014
Lab researching:

Two main areas of research at the moment:

New beginnings

Story | Wednesday 8 January 2014
Researchers from RSB and CSIRO Plant Industry, have taken a second look at where we begin to read genes, leading to the discovery of more than 2,000 new human and mouse proteins.

BSB PhD Exit Seminar: Bacteria-based cancer immunotherapy: A re-emerging strategy with contemporary implications

Event | Fri 28 April 2023
Immunotherapy is a re-emerging alternative to other invasive and debilitating cancer treatments. Monoclonal antibodies that disrupt immune checkpoint molecules, such as PD1 or CTLA4, continually demonstrate great promise.
Dr Diana Stojanovski, University of Melbourne

Mitochondrial Protein Import in Health and Disease

Event | Thu 17 October 2019
Mitochondrial function and cell viability require a functional and healthy mitochondrial proteome.

Chromatin structure and epigenetics in Plasmodium falciparum

Event | Thu 27 June 2019

 The genome of the malaria parasite Plasmodium falciparum is maintained primarily as transcriptionally competent, euchromatin with only rest